TransCode Therapeutics has begun a formal review of strategic options intended to maximize value from the company and its cancer-drug portfolio, led by its Phase 2a candidate TTX-MC138. The review could result in a deal involving an individual drug program, a broader partnership or a transaction involving the company, but TransCode has not announced a specific offer or outcome.
The company has hired Tungsten Advisors as its exclusive financial adviser for the process. TransCode said it does not plan to provide updates unless its board approves a specific transaction or course of action, or it otherwise decides an update is appropriate or required.
Key details
-
Options under review: TransCode is considering licensing or selling individual assets, development and commercialization partnerships, portfolio transactions, a business combination or other strategic arrangements. The review covers TTX-MC138 and the company’s other oncology programs.
-
TTX-MC138 is the lead program: The investigational RNA-based drug is designed to inhibit miR-10b, a molecule associated with metastatic cancer. It is in a Phase 2a trial for people with colorectal cancer who have completed curative-intent treatment, have no disease visible on imaging, but test positive for circulating tumor DNA—a sign of possible residual cancer.
-
Trial enrollment support: The study is being conducted with Quantum Leap Healthcare Collaborative through its PRE-I-SPY program. A separate collaboration announced with Natera on October 13 uses Natera’s Signatera test to help identify eligible patients and support enrollment at participating sites.
-
Earlier study findings: In a Phase 1a dose-escalation study in patients with advanced solid tumors, TransCode reported no dose-limiting toxicities at the evaluated dose levels. In a September update, 10 of 14 patients evaluable for efficacy had stable disease as their best overall response, based on investigator assessment. The company said those preliminary findings require confirmation in larger studies.
-
Phase 2a design: The trial is designed to evaluate TTX-MC138 in up to 45 patients with colorectal cancer who remain or become ctDNA-positive after curative-intent treatment. The drug remains investigational and is not approved for commercial use.
What changes for investors
The immediate change is that TransCode is actively exploring outside transactions for its assets or the company, with an adviser in place to lead that work. No sale, licensing agreement, partnership or other deal has been reached, and the company has not committed to a particular outcome. The strategic review is taking place while TTX-MC138 advances in clinical testing; the disclosed early safety and disease-stability observations are preliminary and do not establish the drug’s effectiveness.